Move over fillers - people are getting facial injections derived from fish sperm

Polynucleotide skin injections—small fragments of salmon or trout DNA marketed as regenerative treatments—are rapidly gaining consumer traction and celebrity endorsement, driving increased demand at aesthetic clinics; sessions cost roughly £200–£500, typically require a three-treatment induction and six- to nine-month top-ups, creating a high-margin, recurring revenue stream for clinics and suppliers. However, clinical evidence remains limited, adverse reactions and cases of scarring have been reported, and products are regulated as medical devices in the UK (not FDA-approved in the US), prompting warnings from industry bodies about untested products and inconsistent administration. For investors, the space presents near-term growth and attractive unit economics but meaningful regulatory, safety and reputational risks that could trigger tighter oversight, liability exposure or consolidation as standards and clinical data evolve.

Analysis

The article documents growing consumer adoption of polynucleotide injections—small fragments of trout or salmon DNA—positioned as regenerative skincare; sessions cost roughly £200–£500, typically require a three-treatment induction and six- to nine-month top-ups, and celebrity endorsements (Charli XCX, members of the Kardashian family, Jennifer Aniston) have helped rapid uptake according to clinic owners who report increased demand over the past 18 months.

Clinical evidence is limited: a small but growing body of studies suggests potential for reducing fine lines, wrinkles and scarring, yet consultant dermatologists warn there is not "good, strong data" and call for larger, multi‑year trials. Reported adverse outcomes include temporary redness, swelling and bruising but also more serious cases of infection, inflammation and scarring (one patient described persistent scarring and pigment change), and practitioners report mixed efficacy with roughly half of patients noticing significant improvement.

Regulatory and market risks are material: polynucleotides are registered as medical devices with the UK MHRA but are not FDA‑approved in the US, and industry bodies (Save Face, British College of Aesthetic Medicine) warn of untested products and inconsistent administration. For investors this implies attractive near‑term unit economics and recurring revenue potential offset by the realistic prospects of tighter oversight, liability exposure and reputational-driven demand shocks as clinical evidence and regulation evolve.

Key Decisions for Investors

• Favor exposure to established clinic chains and reputable suppliers that can demonstrate quality controls and clinical data rather than small unregulated entrants
• Monitor MHRA/FDA regulatory developments, adverse event reports and results from larger clinical trials and reduce or hedge positions if regulators move to reclassify or restrict products
• Limit position size and consider downside protection (e.g., hedges) to mitigate litigation, safety or reputation-driven shocks given reported infections and scarring
• Target companies with proprietary clinical evidence or disciplined medical governance as potential winners to capture the recurring £200–£500 per‑session revenue stream